Literature DB >> 22878004

Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats.

Yutaka Tonomura1, Shuuichi Matsushima, Emi Kashiwagi, Kae Fujisawa, Shingo Takagi, Yoko Nishimura, Ryou Fukushima, Mikinori Torii, Mitsunobu Matsubara.   

Abstract

Cardiotoxicity and musculoskeletal toxicity can be life-threatening, and thus have strong impact on both the development and marketing of drugs. Because the conventional biomarkers such as aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) have low detection power, there has been increasing interest in developing biomarkers with higher detection power. The current study examined the usefulness of several promising biomarkers, cardiac and skeletal muscle troponins (cTnI, cTnT and sTnI), fatty acid binding protein 3 (FABP3) and myosin light chain 3 (MYL3), and compared the obtained data to AST, LDH and CK in rat models treated with various myotoxic and non-myotoxic compounds (isoproterenol, metaproterenol, doxorubicin, mitoxantrone, allylamine, cyclosporine A, cyclophosphamide, aminoglutethimide, acetaminophen, methapyrilene, allylalcohol and α-naphthylisothiocyanate). These promising biomarkers were found to be superior to the conventional biomarkers, as they had a specific and abundant distribution within the heart and/or skeletal muscles; exhibited a positive correlation between the amplitude of increases and the degree of pathological alterations; had higher diagnostic accuracy for detecting pathological alterations; and had the additive effect of improving the diagnostic accuracy of conventional biomarkers. However, these promising biomarkers have several drawbacks including a rapid clearance, the fact that they are affected by renal dysfunction, and different reactivity to the mode of action of individual myotoxicants. In conclusion, the promising biomarkers cTnI, cTnT, FABP3, MYL3, and sTnI demonstrated sensitivity and specificity for cardiac and skeletal myotoxicity that was superior to those of conventional biomarkers, while we should pay attention to the drawbacks of these biomarkers when used in toxicity studies.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878004     DOI: 10.1016/j.tox.2012.07.012

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  12 in total

1.  Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.

Authors:  Kyuri Kim; Naseem Chini; David G Fairchild; Steven K Engle; William J Reagan; Sandra D Summers; Jon C Mirsalis
Journal:  Toxicol Pathol       Date:  2016-09-28       Impact factor: 1.902

2.  Functional brown adipose tissue limits cardiomyocyte injury and adverse remodeling in catecholamine-induced cardiomyopathy.

Authors:  Robrecht Thoonen; Laura Ernande; Juan Cheng; Yasuko Nagasaka; Vincent Yao; Alexandre Miranda-Bezerra; Chan Chen; Wei Chao; Marcello Panagia; David E Sosnovik; Dheeraj Puppala; Antonis A Armoundas; Allyson Hindle; Kenneth D Bloch; Emmanuel S Buys; Marielle Scherrer-Crosbie
Journal:  J Mol Cell Cardiol       Date:  2015-05-09       Impact factor: 5.000

3.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

4.  Sensitive Detection of Cardiac Biomarkers Using a Magnetic Microbead Immunoassay.

Authors:  Christine F Woolley; Mark A Hayes
Journal:  Anal Methods       Date:  2015-08-20       Impact factor: 2.896

Review 5.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

Authors:  Igor Koturbash; William H Tolleson; Lei Guo; Dianke Yu; Si Chen; Huixiao Hong; William Mattes; Baitang Ning
Journal:  Biomark Med       Date:  2015-10-26       Impact factor: 2.851

6.  The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.

Authors:  Eugene Herman; Alan Knapton; Jun Zhang; Joel Estis; John Todd; Steven Lipshultz
Journal:  Pharmacol Res Perspect       Date:  2014-03-03

7.  Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells.

Authors:  Alaaeldin Ahmed Hamza; Mahguob Mohamed Ahmed; Hanan Mohamed Elwey; Amr Amin
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

8.  Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury.

Authors:  Young-Eun Cho; Eun-Ju Im; Pyong-Gon Moon; Esteban Mezey; Byoung-Joon Song; Moon-Chang Baek
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

Review 9.  Management of Statin Intolerance in 2018: Still More Questions Than Answers.

Authors:  Peter P Toth; Angelo Maria Patti; Rosaria Vincenza Giglio; Dragana Nikolic; Giuseppa Castellino; Manfredi Rizzo; Maciej Banach
Journal:  Am J Cardiovasc Drugs       Date:  2018-06       Impact factor: 3.571

10.  Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats.

Authors:  Ryota Tochinai; Kayoko Komatsu; Junta Murakami; Yuriko Nagata; Minoru Ando; Chie Hata; Tomo Suzuki; Shoichi Kado; Toshihide Kobayashi; Masayoshi Kuwahara
Journal:  J Toxicol Pathol       Date:  2018-08-05       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.